National Institute for Health and Care Excellence

Quality statement 2: Venous thromboembolism risk assessment for people with lower limb immobilisation

A significant number of people are discharged after hospital treatment for trauma or orthopaedic surgery with temporary lower limb immobilisation. These people may have an increased risk of VTE, but ...
National Institute for Health and Care Excellence

Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more lines of systemic treatment

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...
National Institute for Health and Care Excellence

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043] ...
National Institute for Health and Care Excellence

Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

symptomatic peripheral arterial disease (they have intermittent claudication with an ankle-brachial index of less than 0.85 at rest, or have had a peripheral arterial revascularisation procedure or an ...
National Institute for Health and Care Excellence

Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. This guidance updates and ...
National Institute for Health and Care Excellence

Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

There is a simple discount patient access scheme for teclistamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer

Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease. Next review: This guidance will be ...
National Institute for Health and Care Excellence

Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment

We have moved Health technology evaluation 6 to become HealthTech guidance 665. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, ...
National Institute for Health and Care Excellence

Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments

Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments. This ...
National Institute for Health and Care Excellence

Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies

There is a simple discount patient access scheme for sacituzumab govetican. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Tirzepatide for treating type 2 diabetes

NICE has recently reviewed the evidence on medicines for type 2 diabetes and has published an update to the NICE guideline on type 2 diabetes in adults: management (NG28). Work is ongoing to address ...